197 related articles for article (PubMed ID: 22584909)
1. Lenalidomide in solid tumors.
Segler A; Tsimberidou AM
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1393-406. PubMed ID: 22584909
[TBL] [Abstract][Full Text] [Related]
2. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
Mariz JM; Esteves GV
Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
[TBL] [Abstract][Full Text] [Related]
3. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
4. The potential of immunomodulatory drugs in the treatment of solid tumors.
Dalgleish A; Galustian C
Future Oncol; 2010 Sep; 6(9):1479-84. PubMed ID: 20919830
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide mode of action: linking bench and clinical findings.
Davies F; Baz R
Blood Rev; 2010 Nov; 24 Suppl 1():S13-9. PubMed ID: 21126632
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide in combination with dexamethasone for the treatment of multiple myeloma after one prior therapy.
Hazarika M; Rock E; Williams G; Dagher R; Sridhara R; Booth B; Farrell A; Justice R; Pazdur R
Oncologist; 2008 Oct; 13(10):1120-7. PubMed ID: 18922829
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide for the treatment of B-cell malignancies.
Chanan-Khan AA; Cheson BD
J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
[TBL] [Abstract][Full Text] [Related]
9. A review of the history, properties, and use of the immunomodulatory compound lenalidomide.
Zeldis JB; Knight R; Hussein M; Chopra R; Muller G
Ann N Y Acad Sci; 2011 Mar; 1222():76-82. PubMed ID: 21434945
[TBL] [Abstract][Full Text] [Related]
10. Properties of thalidomide and its analogues: implications for anticancer therapy.
Teo SK
AAPS J; 2005 Mar; 7(1):E14-9. PubMed ID: 16146335
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide: an update on evidence from clinical trials.
Dimopoulos MA; Terpos E
Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in the treatment of multiple myeloma: a review.
Armoiry X; Aulagner G; Facon T
J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide: patient management strategies.
Hussein MA
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S22-5. PubMed ID: 16344098
[TBL] [Abstract][Full Text] [Related]
14. Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies.
Sharma RA; Steward WP; Daines CA; Knight RD; O'Byrne KJ; Dalgleish AG
Eur J Cancer; 2006 Sep; 42(14):2318-25. PubMed ID: 16899362
[TBL] [Abstract][Full Text] [Related]
15. Role of lenalidomide in the treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma.
Bringhen S; Gay F; Pautasso C; Cerrato C; Boccadoro M; Palumbo A
Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1209-22. PubMed ID: 22862790
[TBL] [Abstract][Full Text] [Related]
17. Novel lenalidomide-based combinations for treatment of multiple myeloma.
Cives M; Simone V; Brunetti O; Longo V; Silvestris F
Crit Rev Oncol Hematol; 2013 Jan; 85(1):9-20. PubMed ID: 22809697
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide: a synthetic compound with an evolving role in cancer management.
Saloura V; Grivas PD
Hematology; 2010 Oct; 15(5):318-31. PubMed ID: 20863427
[TBL] [Abstract][Full Text] [Related]
19. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide in multiple myeloma.
Sirohi B; Powles R
Expert Rev Anticancer Ther; 2009 Nov; 9(11):1559-70. PubMed ID: 19895240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
